Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ$14.81
Market Cap
$1.76B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
335 of 924
Rank in Industry
195 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ARQT Insider Trading Activity
ARQT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $47,560 | 5 | 10 |
Sells | $4,521,306 | 43 | 90 |
Related Transactions
| Watanabe Todd Franklin | See Remarks | 2 | $21,250 | 7 | $1.17M | $-1.15M |
| Matsuda Masaru | See Remark | 2 | $18,543 | 7 | $316,036 | $-297,493 |
| Edwards Larry Todd | SVP Chief Commercial Officer | 1 | $7,767 | 3 | $133,475 | $-125,708 |
| Moore Matthew Richard | SVP and Chief Business Officer | 0 | $0 | 1 | $40,902 | $-40,902 |
| Curran Terrie | director | 0 | $0 | 1 | $94,238 | $-94,238 |
| Topper David Joseph | Chief Financial Officer | 0 | $0 | 1 | $110,264 | $-110,264 |
| Welgus Howard G. | director | 0 | $0 | 10 | $1.09M | $-1.09M |
| Burnett Patrick | See Remarks | 0 | $0 | 13 | $1.57M | $-1.57M |
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; …
Insider Activity of Arcutis Biotherapeutics, Inc.
Over the last 12 months, insiders at Arcutis Biotherapeutics, Inc. have bought $47,560 and sold $4.52M worth of Arcutis Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Arcutis Biotherapeutics, Inc. have bought $13.76M and sold $4.21M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Watanabe Todd Franklin (See Remarks) — $21,250. Matsuda Masaru (See Remark) — $18,543. Edwards Larry Todd (SVP Chief Commercial Officer) — $7,767.
The last purchase of 1,093 shares for transaction amount of $7,767 was made by Edwards Larry Todd (See Remarks) on 2024‑11‑30.
List of Insider Buy and Sell Transactions, Arcutis Biotherapeutics, Inc.
| 2025-03-04 | Sale | Watanabe Todd Franklin | See Remarks | 4,135 0.0034% | $13.28 | $54,930 | +10.30% | |
| 2025-03-04 | Sale | Burnett Patrick | See Remarks | 954 0.0008% | $13.28 | $12,673 | +10.30% | |
| 2025-03-03 | Sale | Watanabe Todd Franklin | See Remarks | 20,880 0.0179% | $13.03 | $272,089 | +14.96% | |
| 2025-03-03 | Sale | Matsuda Masaru | See Remarks | 3,263 0.0028% | $13.03 | $42,520 | +14.96% | |
| 2025-03-03 | Sale | Burnett Patrick | See Remarks | 2,819 0.0024% | $13.03 | $36,735 | +14.96% | |
| 2025-03-03 | Sale | Welgus Howard G. | director | 10,000 0.0086% | $13.00 | $130,048 | +14.96% | |
| 2025-02-03 | Sale | Watanabe Todd Franklin | See Remarks | 19,301 0.0158% | $12.70 | $245,123 | +3.23% | |
| 2025-02-03 | Sale | Matsuda Masaru | See Remarks | 8,338 0.0068% | $12.70 | $105,893 | +3.23% | |
| 2025-02-03 | Sale | Welgus Howard G. | director | 10,000 0.0082% | $12.71 | $127,100 | +3.23% | |
| 2025-02-03 | Sale | Edwards Larry Todd | See Remarks | 2,173 0.0018% | $12.70 | $27,597 | +3.23% | |
| 2025-02-03 | Sale | Burnett Patrick | See Remarks | 12,116 0.0099% | $12.70 | $153,873 | +3.23% | |
| 2025-01-02 | Sale | Welgus Howard G. | director | 10,000 0.0086% | $14.67 | $146,714 | -7.76% | |
| 2024-12-31 | Sale | Burnett Patrick | See Remarks | 1,691 0.0014% | $14.00 | $23,674 | -2.98% | |
| 2024-12-20 | Sale | Watanabe Todd Franklin | See Remarks | 15,000 0.0131% | $15.17 | $227,567 | -8.69% | |
| 2024-12-02 | Sale | Welgus Howard G. | director | 10,000 0.0086% | $12.51 | $125,133 | +8.70% | |
| 2024-11-30 | Watanabe Todd Franklin | See Remarks | 2,038 0.0009% | $7.11 | $14,482 | 0.00% | ||
| 2024-11-30 | Matsuda Masaru | See Remarks | 1,657 0.0008% | $7.11 | $11,775 | 0.00% | ||
| 2024-11-30 | Edwards Larry Todd | See Remarks | 1,093 0.0005% | $7.11 | $7,767 | 0.00% | ||
| 2024-11-22 | Sale | Burnett Patrick | See Remarks | 16,023 0.0136% | $10.14 | $162,515 | +32.15% | |
| 2024-11-19 | Sale | Matsuda Masaru | See Remarks | 1,775 0.0015% | $9.68 | $17,190 | +31.44% |
Total: 188
*Gray background shows transactions not older than one year
Insider Historical Profitability
26.62%
| Watanabe Todd Franklin | See Remarks | 930114 0.784% | $13.77M | 3 | 47 | +6.79% |
| Matsuda Masaru | See Remarks | 209429 0.1765% | $3.1M | 2 | 13 | |
| Edwards Larry Todd | See Remarks | 135555 0.1143% | $2.01M | 1 | 3 | |
| Heron Patrick J | director | 8785284 7.4051% | $130.11M | 3 | 0 | <0.0001% |
| Frazier Life Sciences VIII, L.P. | 10 percent owner | 8764232 7.3874% | $129.8M | 2 | 0 | +140.17% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.03B | |
$8,217,280 | 112 | 46.33% | $1.31B | |
$831,902,292 | 108 | 9.34% | $1.56B | |
$20,297,544 | 73 | 103.06% | $1.58B | |
$11,583,737 | 45 | 49.75% | $1.7B |
ARQT Institutional Investors: Active Positions
| Increased Positions | 105 | +46.05% | 15M | +11.93% |
| Decreased Positions | 97 | -42.54% | 15M | -11.86% |
| New Positions | 47 | New | 5M | New |
| Sold Out Positions | 32 | Sold Out | 3M | Sold Out |
| Total Postitions | 236 | +3.51% | 129M | +0.06% |
ARQT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Jennison Associates Llc | $168,932.00 | 10.37% | 12.34M | +676,295 | +5.8% | 2024-12-31 |
| Suvretta Capital Management, Llc | $156,054.00 | 9.58% | 11.4M | +677,627 | +6.32% | 2024-12-31 |
| Rubric Capital Management Lp | $150,134.00 | 9.22% | 10.97M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $125,244.00 | 7.69% | 9.15M | +119,002 | +1.32% | 2024-12-31 |
| Frazier Life Sciences Management, L.P. | $120,271.00 | 7.38% | 8.79M | 0 | 0% | 2024-12-31 |
| Polar Capital Holdings Plc | $100,996.00 | 6.2% | 7.38M | +493,009 | +7.16% | 2024-12-31 |
| Vanguard Group Inc | $88,173.00 | 5.41% | 6.44M | -521,920 | -7.5% | 2024-12-31 |
| State Street Corp | $67,775.00 | 4.16% | 4.95M | -690,906 | -12.25% | 2024-12-31 |
| Morgan Stanley | $58,099.00 | 3.57% | 4.24M | +462,716 | +12.24% | 2024-12-31 |
| Gilder Gagnon Howe & Co Llc | $53,432.00 | 3.28% | 3.9M | +349,153 | +9.82% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.